Daryush Purrahman

Ahvaz Jundishapur University of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Mohammad‐Reza Mahmoudian‐Sani

Ahvaz Jundishapur University of Medical Sciences

Najmaldin Saki

Ahvaz Jundishapur University of Medical Sciences

ŁA

Łukasz A. Poniatowski

Medical University of Warsaw

Piotr Wojdasiewicz

Medical University of Warsaw

Dariusz Szukiewicz

Medical University of Warsaw

Paweł Turczyn

National Institute of Geriatrics, Rheumatology and Rehabilitation

Ali Shojaeian

Hamedan University of Medical Sciences

Bijan Keikhaei

Ahvaz Jundishapur University of Medical Sciences

Habib Haybar

Ahvaz Jundishapur University of Medical Sciences

Homayon Yousefi

Ahvaz Jundishapur University of Medical Sciences

Cooperative Institutions

Ahvaz Jundishapur University of Medical Sciences

Medical University of Warsaw

National Institute of Geriatrics, Rheumatology and Rehabilitation

Shahid Beheshti University of Medical Sciences

Isfahan University of Medical Sciences

Shahrekord University of Medical Sciences

Hamedan University of Medical Sciences

Imam Khomeini Hospital

Iran University of Medical Sciences

Cardiovascular Research Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Long non-coding RNA signatures and related signaling pathway in T-cell acute lymphoblastic leukemia

Clinical & Translational Oncology (2022)

Homayon Yousefi Daryush Purrahman Mohammad Jamshidi Elena Lak Bijan Keikhaei

10.1007/s12094-022-02886-9

Cite

Citations (10)

The role of inflammatory mediators in the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome

Molecular Biology Reports (2022)

Daryush Purrahman Łukasz A. Poniatowski Piotr Wojdasiewicz Fathi Mohammad Reza Homayon Yousefi

Etiology

Pathogenesis

Adenitis

10.1007/s11033-022-07352-x

Cite

Citations (3)

Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases

Journal of Inflammation (2023)

Ali Saeedi‐Boroujeni Daryush Purrahman Ali Shojaeian Łukasz A. Poniatowski Fatemeh Rafiee

Abstract Immune dysregulation has been identified as a critical cause of the most common types of cardiovascular diseases (CVDs). Notably, the innate and adaptive immune responses under physiological conditions are typically regulated with high sensitivity to avoid the exacerbation of inflammation, but any dysregulation can probably be associated with CVDs. In this respect, progranulin (PGRN) serves as one of the main components of the regulation of inflammatory processes, which significantly contributes to the immunopathogenesis of such disorders. PGRN has been introduced among the secreted growth factors as one related to wound healing, inflammation, and human embryonic development, as well as a wide variety of autoimmune diseases. The relationship between the serum PGRN and TNF-α ratio with the spontaneous bacterial peritonitis constitute one of the independent predictors of these conditions. The full-length PGRN can thus effectively reduce the calcification of valve interstitial cells, and the granulin precursor (GRN), among the degradation products of PGRN, can be beneficial. Moreover, it was observed that, PGRN protects the heart against ischemia-reperfusion injury. Above all, PGRN also provides protection in the initial phase following myocardial ischemia-reperfusion injury. The protective impact of PGRN on this may be associated with the early activation of the PI3K/Akt signaling pathway. PGRN also acts as a protective factor in hyperhomocysteinemia, probably by down-regulating the wingless-related integration site Wnt/β-catenin signaling pathway. Many studies have further demonstrated that SARS-CoV-2 (COVID-19) has dramatically increased the risks of CVDs due to inflammation, so PGRN has drawn much more attention among scholars. Lysosomes play a pivotal role in the inflammation process, and PGRN is one of the key regulators in their functioning, which contributes to the immunomodulatory mechanism in the pathogenesis of CVDs. Therefore, investigation of PGRN actions can help find new prospects in the treatment of CVDs. This review aims to summarize the role of PGRN in the immunopathogenesis of CVD, with an emphasis on its treatment.

Immune Dysregulation

10.1186/s12950-023-00327-0

Cite

Citations (17)

The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme

Cells (2024)

Łukasz A. Poniatowski Michał Woźnica Piotr Wojdasiewicz Aneta Mela-Kalicka Katarzyna Romanowska‐Próchnicka

Glioblastoma multiforme (GBM) represents the most common and aggressive malignant form of brain tumour in adults and is characterized by an extremely poor prognosis with dismal survival rates. Currently, expanding concepts concerning the pathophysiology of GBM are inextricably linked with neuroinflammatory phenomena. On account of this fact, the identification of novel pathomechanisms targeting neuroinflammation seems to be crucial in terms of yielding successful individual therapeutic strategies. In recent years, the pleiotropic growth factor progranulin (PGRN) has attracted significant attention in the neuroscience and oncological community regarding its neuroimmunomodulatory and oncogenic functions. This review of the literature summarizes and updates contemporary knowledge about PGRN, its associated receptors and signalling pathway involvement in GBM pathogenesis, indicating possible cellular and molecular mechanisms with potential diagnostic, prognostic and therapeutic targets in order to yield successful individual therapeutic strategies. After a review of the literature, we found that there are possible PGRN-targeted therapeutic approaches for implementation in GBM treatment algorithms both in preclinical and future clinical studies. Furthermore, PGRN-targeted therapies exerted their highest efficacy in combination with other established chemotherapeutic agents, such as temozolomide. The results of the analysis suggested that the possible implementation of routine determinations of PGRN and its associated receptors in tumour tissue and biofluids could serve as a diagnostic and prognostic biomarker of GBM. Furthermore, promising preclinical applications of PGRN-related findings should be investigated in clinical studies in order to create new diagnostic and therapeutic algorithms for GBM treatment.

Pathogenesis

Temozolomide

Therapeutic approach

10.3390/cells13020124

Cite

Citations (1)

The Role of Rosavin in the Pathophysiology of Bone Metabolism

Piotr Wojdasiewicz Paweł Turczyn Anna Lach-Gruba Łukasz A. Poniatowski Daryush Purrahman

Rosavin, a phenylpropanoid in Rhodiola rosea's rhizome, an adaptogen, is known for enhancing the body's response to environmental stress. It significantly affects cellular metabolism in health and many diseases, particularly influencing bone tissue metabolism. In vitro, rosavin inhibits osteoclastogenesis, disrupts F-actin rings formation, and lowers osteoclastogenesis-related gene expression (cathepsin K, CTR, TRAF6, TRAP, MMP-9). It also impedes NFATc1, c-Fos, NF-κB, and MAPK signaling pathways, and blocks phosphorylation processes crucial for bone resorption. Moreover, rosavin promotes osteogenesis, osteoblast differentiation and increases Runx2 and OCN expression. In vivo studies show its effectiveness in enhancing BMD in PMOP mice, re-straining osteoclast maturation, and increasing active osteoblast percentage in bone tissue. It modulates mRNA expressions (increasing EEF2 and decreasing HDAC1, thereby activating os-teoprotective epigenetic mechanisms) and alters various serum markers, including decrease of CTX-1, TRAcp5b, RANKL, M-CSF, TRAP, and increase of ALP and OCN. Additionally, when combined with zinc and probiotics, it reduces pro-osteoporotic MMP-3, IL-6, TNF-α, and en-hances anti-osteoporotic IL-10 and TIMP3 expressions. This paper aims to systematically review rosavin's impact on bone tissue metabolism, exploring its potential in osteoporosis prevention and treatment, and suggesting future research directions.

Bone remodeling

Cathepsin K

RUNX2

10.20944/preprints202401.0295.v1

Cite

Citations (3)

The Role of Rosavin in the Pathophysiology of Bone Metabolism

International Journal of Molecular Sciences (2024)

Piotr Wojdasiewicz Paweł Turczyn Anna Lach-Gruba Łukasz A. Poniatowski Daryush Purrahman

Rosavin, a phenylpropanoid in Rhodiola rosea’s rhizome, and an adaptogen, is known for enhancing the body’s response to environmental stress. It significantly affects cellular metabolism in health and many diseases, particularly influencing bone tissue metabolism. In vitro, rosavin inhibits osteoclastogenesis, disrupts F-actin ring formation, and reduces the expression of osteoclastogenesis-related genes such as cathepsin K, calcitonin receptor (CTR), tumor necrosis factor receptor-associated factor 6 (TRAF6), tartrate-resistant acid phosphatase (TRAP), and matrix metallopeptidase 9 (MMP-9). It also impedes the nuclear factor of activated T-cell cytoplasmic 1 (NFATc1), c-Fos, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and mitogen-activated protein kinase (MAPK) signaling pathways and blocks phosphorylation processes crucial for bone resorption. Moreover, rosavin promotes osteogenesis and osteoblast differentiation and increases mouse runt-related transcription factor 2 (Runx2) and osteocalcin (OCN) expression. In vivo studies show its effectiveness in enhancing bone mineral density (BMD) in postmenopausal osteoporosis (PMOP) mice, restraining osteoclast maturation, and increasing the active osteoblast percentage in bone tissue. It modulates mRNA expressions by increasing eukaryotic translation elongation factor 2 (EEF2) and decreasing histone deacetylase 1 (HDAC1), thereby activating osteoprotective epigenetic mechanisms, and alters many serum markers, including decreasing cross-linked C-telopeptide of type I collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRACP5b), receptor activator for nuclear factor κ B ligand (RANKL), macrophage-colony-stimulating factor (M-CSF), and TRAP, while increasing alkaline phosphatase (ALP) and OCN. Additionally, when combined with zinc and probiotics, it reduces pro-osteoporotic matrix metallopeptidase 3 (MMP-3), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α), and enhances anti-osteoporotic interleukin 10 (IL-10) and tissue inhibitor of metalloproteinase 3 (TIMP3) expressions. This paper aims to systematically review rosavin’s impact on bone tissue metabolism, exploring its potential in osteoporosis prevention and treatment, and suggesting future research directions.

Cathepsin K

Tartrate-resistant acid phosphatase

Bone remodeling

10.3390/ijms25042117

Cite

Citations (5)

Prognostic significance of aberrant CD5 expression in B-cell leukemia

Oncology Reviews (2019)

Kaveh Jaseb Daryush Purrahman Saeid Shahrabi Majid Ghanavat Hadi Rezaeean

Aberrant expression of CD5 (as a T-cell marker) is seen in some leukemia and lymphoma of B lineage origin. Given that the signaling resulting from the expression of this marker plays an essential role in the development of leukemia and lymphoma, evaluating the expression of this marker is of paramount importance. Therefore, our goal in this study was to investigate the prognostic importance of CD5 expression in B-cell leukemia and lymphoma. We evaluate CD5 expression in normal and leukemic B-cells by identifying relevant literature through a PubMed search (1998-2018) of English language papers using the terms: ‘CD5,’ ‘B-cell,’ ‘Leukemia,’ and ‘Lymphoma.’ We are doing this thorough comparison of results from CD5 positive and negative cases to make a correct decision about prognostic importance of CD5 expression in these malignancies. In a number of B-cell malignancies, CD5 is expressed in varying degrees. Due to the different origins and characteristics of these malignancies, the results of CD5 expression evaluations are heterogeneous and impossible to generalize. However, CD5 expression is sometimes associated with clinicopathologic findings, more invasive clinical course, and even resistance to treatment (specifically in DLBCL) among CD5- positive patients, which appears to be a function of CD5 signaling and its downstream factors such as STAT3. Depending on the type of malignancy, CD5 expression is associated with good or bad prognosis, which can be used as an auxiliary prognostic factor to assess the clinical course of B-cell malignancies. Moreover, the difference in expression levels of CD5 in a variety of B-cell malignancies allows for differential diagnosis of these malignancies, which can be helpful when diagnosis is difficult.

CD5

10.4081/oncol.2019.400

Cite

Citations (12)

The Role of Progranulin (PGRN) in the Pathogenesis of Ischemic Stroke

Cellular and Molecular Neurobiology (2023)

Daryush Purrahman Ali Shojaeian Łukasz A. Poniatowski Bartłomiej Piechowski‐Jóźwiak Mohammad‐Reza Mahmoudian‐Sani

10.1007/s10571-023-01396-8

Cite

Citations (4)

The prognostic potential of long noncoding RNA XIST in cardiovascular diseases: a review

Personalized Medicine (2024)

Habib Haybar Ehsan Sarbazjoda Daryush Purrahman Mohammad‐Reza Mahmoudian‐Sani Najmaldin Saki

There is a significant mortality rate associated with cardiovascular disease despite advances in treatment. long Non-coding RNAs (lncRNAs) play a critical role in many biological processes and their dysregulation is associated with a wide range of diseases in which their downstream pathways are disrupted. A lncRNA X-inactive specific transcript (XIST) is well known as a factor that regulates the physiological process of chromosome dosage compensation for females. According to recent studies, lncRNA XIST is involved in a variety of cellular processes, including apoptosis, proliferation, invasion, metastasis, oxidative stress and inflammation, through molecular networks with microRNAs and their downstream targets in neoplastic and non-neoplastic diseases. Because these cellular processes play a role in the pathogenesis of cardiovascular diseases, we aim to investigate the role that lncRNA XIST plays in this process. Additionally, we wish to determine whether it is a prognostic factor or a potential therapeutic target in these diseases.

XIST

Dosage compensation

10.1080/17410541.2024.2360380

Cite

Citations (0)

Omega-3 fatty acids in the treatment of spinal cord injury: untapped potential for therapeutic intervention?

Molecular Biology Reports (2022)

Paweł Turczyn Piotr Wojdasiewicz Łukasz A. Poniatowski Daryush Purrahman Maria Maślińska

10.1007/s11033-022-07762-x

Cite

Citations (10)